Core Viewpoint - Nanwei Medical's stock price has shown a significant increase of 28.14% year-to-date, with a recent uptick of 2.04% on December 24, 2023, indicating positive market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Nanwei Medical achieved a revenue of 2.381 billion yuan, reflecting a year-on-year growth of 18.29% [2]. - The net profit attributable to the parent company for the same period was 509 million yuan, marking a year-on-year increase of 12.90% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Nanwei Medical increased to 12,500, up by 1.38% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 1.36% to 15,009 shares [2]. Dividend Distribution - Since its A-share listing, Nanwei Medical has distributed a total of 978 million yuan in dividends, with 664 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 3.6594 million shares as a new shareholder [3]. - Huabao Zhongzheng Medical ETF (512170) is the seventh-largest circulating shareholder, holding 3.2232 million shares, which is a decrease of 459,000 shares from the previous period [3]. - Zhonggeng Value Pioneer Stock (012930) is the eighth-largest circulating shareholder, holding 3.0087 million shares, with an increase of 103,000 shares compared to the previous period [3].
南微医学涨2.04%,成交额9928.56万元,主力资金净流出662.07万元